Vaping Triggers Subclinical Lung Vascular Strain in Young Adults: Alberta Data Exposes Gaps in Harm-Reduction Claims

University of Alberta researchers published an observational cross-sectional study in CHEST comparing 20 young never-smokers who vaped for a mean 3.4 years against 20 matched controls. Standard spirometry remained normal, yet e-cigarette users exhibited reduced lung diffusion capacity, lower breathing efficiency, and markedly earlier dyspnea on incremental cycle-ergometer testing equivalent to a brisk walk. Because the design is observational with n=40 and no randomization or longitudinal follow-up, causal inference remains limited; unmeasured confounding from undisclosed flavorings or device wattage cannot be excluded. The findings align with earlier small cohort data from the 2022 American Journal of Respiratory and Critical Care Medicine (n=52) showing reduced pulmonary capillary blood volume in exclusive vapers and a 2023 multicenter European Respiratory Journal analysis linking propylene glycol aerosols to endothelial dysfunction in vitro. Lung maturation continues until approximately age 25; repeated exposure to glycerin pyrolysis products and unregulated flavor volatiles during this window may produce lasting vascular remodeling not captured by routine screening. Public-health messaging that positioned e-cigarettes solely as cessation aids overlooked uptake among nicotine-naïve youth, now exceeding conventional smoking prevalence in multiple high-income countries. Larger prospective cohorts with imaging and biomarker endpoints are required before concluding that early cardiopulmonary changes inevitably progress to COPD or pulmonary hypertension.